Caisse DE Depot ET Placement DU Quebec Purchases Shares of 27,900 argenx SE (NASDAQ:ARGX)

Caisse DE Depot ET Placement DU Quebec acquired a new stake in shares of argenx SE (NASDAQ:ARGX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 27,900 shares of the company's stock, valued at approximately $17,158,000.

A number of other institutional investors also recently made changes to their positions in the business. Wilmington Savings Fund Society FSB bought a new position in argenx during the 3rd quarter valued at approximately $652,000. GAMMA Investing LLC grew its holdings in argenx by 44.8% during the 4th quarter. GAMMA Investing LLC now owns 252 shares of the company's stock valued at $155,000 after buying an additional 78 shares in the last quarter. Central Pacific Bank Trust Division purchased a new stake in shares of argenx during the 4th quarter worth approximately $615,000. Fulton Bank N.A. bought a new stake in shares of argenx in the 4th quarter valued at approximately $226,000. Finally, Assenagon Asset Management S.A. raised its holdings in shares of argenx by 21.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 34,955 shares of the company's stock worth $21,497,000 after buying an additional 6,161 shares during the period. Hedge funds and other institutional investors own 60.32% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on ARGX shares. Piper Sandler raised their price target on argenx from $620.00 to $725.00 and gave the stock an "overweight" rating in a report on Tuesday, January 7th. Wells Fargo & Company upped their price objective on shares of argenx from $723.00 to $741.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. Deutsche Bank Aktiengesellschaft raised shares of argenx from a "sell" rating to a "hold" rating in a report on Wednesday, March 12th. William Blair restated an "outperform" rating on shares of argenx in a research report on Friday, February 28th. Finally, Wedbush reiterated an "outperform" rating and issued a $715.00 price objective on shares of argenx in a report on Friday, April 11th. Three analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $699.28.

argenx Price Performance

argenx stock traded down $41.54 during trading hours on Tuesday, hitting $615.11. The company had a trading volume of 476,926 shares, compared to its average volume of 310,514. The firm has a market cap of $37.56 billion, a PE ratio of -698.99 and a beta of 0.57. argenx SE has a one year low of $352.77 and a one year high of $678.21. The firm has a 50-day moving average of $598.99 and a 200 day moving average of $612.98.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $761.22 million for the quarter, compared to analysts' expectations of $678.52 million. As a group, research analysts expect that argenx SE will post 3.13 earnings per share for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.